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The aim of this study was to evaluate the diagnostic value of a new tumour marker, cytokeratin fragment 19 
(CYFRA 21-l), in bronchoalveolar lavage fluid (BALF) for the diagnosis of lung cancer. The cross-sectional study 
included 36 patients with lung cancer, 19 with benign lung diseases and 13 control subjects. In the group with cancer, 
BAL was performed in the cancer-involved lung and in the opposite lung. Results in BALF were expressed both 
as absolute concentrations (ng ml ~ ‘) and referred to total protein (TP) (ng mg ’ TP), and results in plasma were 
expressed in ng ml ~ ‘. In BALF, there was no significant difference between cancer and control groups. Using the 
95th percentile of levels obtained in benign lung disease in BALF (specificity 95%) as the cut-off point, the sensitivity 
of CYFRA 21-1 was 13%. Positive and negative predictive values (PPV and NPV) at different pretest probabilities, 
and positive and negative gains were obtained applying a Bayesian analysis. Results showed low positive gains for 
PPV (maximal increase of 22%) and almost none for NPV (negative gains ~5%). In plasma, CYFRA 21-1 provided 
a sensitivity of 65%. The combination of BALF and plasma tumour marker levels showed a sensitivity of 69%. 
Therefore, measurement of CYFRA 21-1 in BALF has poor diagnostic value in lung cancer. 
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Introduction 
Determinations of tumour markers (TMs) have been used 
in neoplastic diseases to evaluate their potential as diagnos- 
tic tests. However, research on lung cancer, performed in 
plasma or serum, has proven that their value is limited 
because they lack sensitivity as screening tests and are not 
specific enough to discriminate between neoplastic and 
benign conditions (l-3). 
A new approach to improving the diagnostic yield con- 
sists of assaying TMs in fluid recovered from washing the 
involved organs or from tissue cultures. In lung cancer, 
obtaining bronchoalveolar lavage fluid (BALF) makes it 
possible to assay TMs from airways where neoplastic 
changes take place. Although some previous reports per- 
formed in BALF showed better results than in serum with 
carcinoembryonic antigen (CEA) and squamous cell carci- 
noma antigen (SCC), posterior studies did not seem to 
confirm these findings (446). CYFRA 21-1, a new TM 
assayed in lung cancer, is a cytokeratin present in all 
histological types of lung cancer, and distributed in simple 
or pseudostratified epithelium such as the surface of 
tracheobronchial epithelial airway (7). This TM has proven 
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to be superior to CEA and SCC in blood samples @-lo), 
but prior to the present study, it had not been studied in 
BALF. The aim of the present study was to investigate the 
diagnostic value of CYFRA 21-1 in lung cancer, using a 
Bayesian analysis (11). The authors hypothesized that 
CYFRA 21-1 assayed in BALF, as this was obtained in the 
airway where the tumour is located, would offer more 
diagnostic information. For this purpose, the levels of TMs 
were determined in BALF and plasma in three groups: 
(a) patients with unilateral lung cancer; (b) patients with 
benign lung disease; and (c) control subjects without bron- 
chopulmonary disease. In the cancer group, TMs in BALF 
from the opposite lung were also measured, in order to 
compare the results with those from the cancer-involved 
lung. 
Subjects and Methods 
SUBJECTS 
The authors designed a prospective cross-sectional study on 
three groups of subjects, recruited from inpatients and 
outpatients who were scheduled to have a diagnostic bron- 
choscopy exploration. Thirty-six patients had lung cancer, 
19 had benign lung disease, and 13 were control subjects, 
smokers and non-smokers. The demographic characteristics 
of the groups are shown in Table 1. Informed written 
consent was obtained from all subjects to undergo BAL for 
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TABLE 1. Demographic characteristics of the groups 
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Sex 
N Age (M:F) Non-smoker Smoker Ex-smoker 
Cancer 36 61 &9 35:l 2 24 10 
BLD 19 54* 15 13:6 8 7 4 
CG 13 59 zk 7 12:l 2 6 5 
Values are expressed in mean f SD. BLD, benign lung disease; CG, control group. 
research purposes during fibre optic bronchoscopy. Patients 
without a definitive diagnosis of cancer or benign lung 
disease were excluded from the study. Patients with severe 
renal or/and liver failure were also excluded because TM 
concentrations can increase in blood (7). Plasma specimens 
were obtained at the time of bronchoscopy. 
Patients with Lung Cancer 
Thirty-six consecutive patients with a lung tumour or 
infiltrative mucosal appearance were selected. Only unilat- 
eral and proven neoplastic diseases were included. Histo- 
logic cell types comprised 19 squamous cell carcinomas, six 
adenocarcinomas, six small cell carcinomas, three large cell 
carcinomas and two undifferentiated carcinomas. 
Patients with Benign Lung Diseases 
Nineteen patients with benign lung disease and without 
prior neoplastic disease were included. They had: pneumo- 
nia (3), bronchiectasis (3), idiopathic interstitial pneumoni- 
tis (3) sarcoidosis (2), tuberculosis (2) chronic obstructive 
pulmonary disease (2), hypersensitivity pneumonitis (l), 
eosinophilic pneumonia (l), pneumoconiosis (1) and 
thromboembolic pulmonary disease with pulmonary infarct 
(1). Patients with different benign processes were selected 
because these diseases can be associated with lung cancer or 
can mimic it, thus making a differential diagnosis necessary. 
Control Subjects 
Thirteen matched subjects undergoing fibre-optic bron- 
choscopy for persistent cough ad previous mild haemoptic 
sputum were included. None showed evidence of concomi- 
tant infections or neoplastic disease on the chest roent- 
genogram, routine analysis or endoscopic exploration, and 
their spirometric parameters were normal. There were no 
endobronchial lesions or cases of active haemoptysis. Nine 
subjects had haemoptysis because of acute bronchitis, and 
four had psychogen cough. 
METHODS 
Local anaesthesia of the nasopharynx and larynx was 
performed using aerosolized lignocaine. A fibre-optic bron- 
choscope (Olympus BFIO; Olympus Corp, NY, U.S.A.) 
was introduced transnasally and wedged under direct 
vision. In patients with lung cancer, the bronchoscope was 
wedged into the airway at the tumour site with the tumour 
visible, and into the corresponding bronchus of the oppo- 
site lung to do the BAL. Only patients in whom the 
bronchial caliber permitted BAL were used in this study. In 
patients with focal parenchymal lung disease, the broncho- 
scope was placed in a bronchus leading to the involved 
segment. In patients with homogeneous diffuse abnormali- 
ties and in controls, the bronchoscope was wedged into the 
right middle lobe. Two 50-ml aliquots of sterile normal 
saline solution, at room temperature, were then instilled 
and aspirated gently by mechanical suction after each 
instillation, and the recovered fluid was collected in a 
siliconized vessel. All aliquots, including the first one, were 
used. Bronchoalveolar lavage was performed in all subjects 
prior to brushing or biopsy to avoid contamination with 
blood. 
The lavage fluid was immediately filtered through a nylon 
gauze (Nytal tissue), centrifuged for 10 minutes at 500 g to 
obtain a cell pellet, and the supernatant was decanted and 
stored at - 70°C until CYFRA 21-1 analysis. All samples, 
BALF and plasma specimens, were labelled with a number 
code blinded to the laboratory personal. Measurements of 
CYFRA 21-1 and total proteins were carried out simul- 
taneously at the end of the study. 
Tumouv Marker Assays 
The CYFRA 21-1 concentrations in BALF and plasma 
were measured by a specific ELISA immunoassay called 
Enzymum-Test CYFRA 2 1 - 1 (Boehringer Mannheim, 
Mannheim, Germany). The test is based on a two-step 
sandwich assay using streptavidin-biotin technology and 
performed at 25°C on ES 600 multibatch analysers. Cyto- 
keratin 19 is recognized by two mouse antibodies, KS 19-1 
and MB 19-21, directed against two different epitopes of a 
fragment of cytokeratin subunit 19, which is referred to 
CYFRA 21-1. Sample, 35 and 700 ul of incubation solu- 
tion, together with biotinylated antibody (MAK 19-l), are 
incubated in streptavidin-coated polystyrene tubes for 
30 min. After aspiration and washing, incubation solution 
is added together with antibody-horseradish peroxidase 
conjugate (BM 19-21). After 30 min incubation time, the 
tubes are aspirated and washed again. Finally, ABTS 
(2,2-azino-bis[3-ethyl-benzthiazoline-sulphonic acid-(6)] di- 
ammonium salt)-substrate solution is added and incubated 
for 60 min. Absorbance is read at 422 nm and the CYFRA 
21-l concentration is calculated from the standard curve. 
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TABLE 2. CYFRA 21-1 in bronchoalveolar lavage (BAL) fluid and plasma 
CYFRA (BAL) CYFRA (BAL) TP 
(ng ml - ‘) (ng mg ~ ’ TP) (mg ml- ‘) 
CYFRA 
(plasma) 
(ng ml - ‘) 
Cancer 
involved 
opposite 
BLD 
CG 
86 105 0.6 
25 78 0.46 
*Pco~oo8 *P=NS *p<o.o01 
84 141 0.7 
31 109 0.37 
**P=NS **P=NS **p<o.o3 
4.2 
1.4 
1.5 
**P<o~ooo1 
TP, total protein; BLD, benign lung disease; CG, control group; NS, not significant: “P, statistical 
differences between involved and opposite lung; **P, statistical differences among three groups. 
Values are expressed as medians. 
The sensitivity of the assays was 0.3 ng ml - ‘. None of 
the samples were concentrated for determination. Total 
protein (TP) content in BALF was determined by the 
Lowry method in order to correct the dilution factor. 
CYFRA 21-1 in BALF was expressed both as ng mll i 
BALF and as ng mg - ’ TP. 
Statistical Analysis 
Data were introduced in a database (DBASE III plus) and 
all calculations were made using a statistical package 
(SPSS) for personal computers. The Kolmogorov-Smirnov 
test was used to evaluate the distribution of CYFRA 21-1. 
Data on CYFRA are expressed as medians or percentiles 
because they were not normally distributed. Therefore, 
non-parametrical statistical analysis was used to compare 
the results between groups (12). Comparisons of the cancer- 
involved and non-involved lungs were made with the 
T-Wilcoxon test for paired samples. Comparisons between 
the three groups studied were assessed by a Kruskal-Wallis 
test. A probability value of less than 0.05 was considered 
significant. Spearman’s ranks correlation test was used to 
evaluate a possible association between CYFRA 21-1 in 
plasma and in BALF. 
The sensitivity of TM was calculated with a 2 x 2 contin- 
gency table, using the 95th percentile of levels obtained in 
benign lung disease as the cut-off point (specificity of 95%). 
A Bayesian analysis (12) was performed to obtain positive 
and negative predictive values (PPV and NPV) according to 
the following formulas: 
PPV= 
sensitivity X prevalence 
[sensitivity X prevalence] 
+ [( 1 -specificity) X (l-prevalence)] 
NPV= 
specificity X (1 -prevalence) 
[specificity X (1 -prevalence)] 
+ [( 1 -sensitivity) x prevalence] 
Positive and negative gains, at different prevalences, 
are calculated. Positive gains are (PPV - prevalence), and 
negative gains are [NPV - (1 - prevalence)]. 
Results 
Demographic data are expressed in Table 1. The results 
of CYFRA 21-1 are expressed as percentiles (medians), 
both in BALF and plasma (Table 2). Plasma levels were 
significantly higher in the cancer group (P<O.OOOl). 
Absolute Concentrations in BALF 
The absolute concentrations of CYFRA 21-1 in BALF are 
expressed in Table 2. There were no statistical differences 
between the three groups. However, the tumour-involved 
lung showed significantly higher levels than the opposite 
lung (P<O.O08). 
Relative Concentrations in BALF 
CYFRA 21-1 levels referred to the TP concentration of 
BALF (ng mg ~ ’ TP) are shown in Table 2. Total protein 
showed significant differences between the three groups 
with higher levels in patients with benign lung disease and 
in tumour-involved lungs (P<O.O3). In lung cancer group, 
TP was higher in tumour-involved lung with respect to the 
opposite one (PiO.001). CYFRA 21-1 did not show stat- 
istical differences between the three groups. However, 
patients with cancer did not have significantly higher levels 
in their tumour-involved lung than in the opposite lung 
(P>O.O5) (Fig. 1). 
Diagnostic Value of CYFRA 21-l in Lung Cancer 
With the 95th percentile of the benign lung disease as the 
cut-off value in BALF (CYFRA 21-1: 446 ng rng- I), the 
sensitivity was 13% for CYFRA 21-1 (95% confidence 
interval 4-28%) at a specificity of 95% (95% confidence 
interval 74-99%). The sensitivity in plasma was 65% at 
95% specificity. Using both BALF and plasma levels, the 
sensitivity increases to 69%. Positive (PPV) and negative 
predictive values (NPV), at different pretest probabilities, 
and positive and negative gains are shown in Fig. 2. 
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FIG. 1 CYFRA 21-1 relative values (ng mg - ‘) in bronchoalveolar lavage fluid of tumour-involved lung (TIL), cancer 
opposite lung (OL), benign lung diseases group (BLD) and control group (CG). Horizontal lines represent the 50th per- 
centile or median. No significant differences were found between any group. 
Low positive and negative gains were obtained for PPV 
(maximal increase of 22%) and almost none for NPV 
(negative gain 15%). There was no significant correlation 
between CYFRA 21-1 levels in BALF and plasma. 
There was no significant difference when the results of 
each histologic cell type were compared. Even CYFRA 
21-1, which showed a sensitivity of 10% for the squamous 
cell carcinoma, remained basically the same. When consid- 
ering the TNM stage of cancer, no significant correlation 
was found either. 
Discussion 
In the present study, the main finding was the low diagnos- 
tic value for lung cancer of CYFRA 21-1 in BAL, despite 
the fact that a better diagnostic value in blood was also 
confirmed (7,10,13). To the authors’ knowledge, this is the 
first study performed with CYFRA 21-1 in this fluid in lung 
cancer. In the valuation of the diagnostic value, two control 
groups (benign lung diseases and control subjects), and the 
opposite lung as internal control, were used. 
In a prior report (14), CYFRA 21-1, CEA and SCC were 
determined in blood in patients with lung cancer; higher 
sensitivity was obtained for CYFRA 21-1 than for CEA 
and SCC. Unfortunately, in the present report, the levels of 
CY FRA 2 1 - 1 in BALF are similar in lungs bearing a cancer 
and in benign lung disease. Moreover, CYFRA 21-1 in 
BALF showed no better profile in squamous cell carci- 
noma, while it was demonstrated in blood. When consider- 
ing the TMN stage of cancer and CYFRA 21-1 levels in 
BALF, no significant correlation was found either. How- 
ever, since not many cases of each histological type are 
included, a possible beta error might be considered. To 
calculate sensitivity, a high specificity was chosen and 
only the benign disease group was selected to avoid over- 
estimation of specificity. The authors chose 95% specificity 
because when a disease is suspected, a test with very high 
specificity is more adequate. In fact, when cancer is sus- 
pected, the highest specificity must be recommended. These 
are the reasons for selecting the 95th percentile of the levels 
obtained in benign lung disease as the cut-off value (specifi- 
city of 95X), and not a ROC curve, another method to 
obtained the cut-off point. All calculations were based on 
relative values as usually made (15-l 8). The combination of 
BALF and blood results for CYFRA 21-1 proved to have a 
higher sensitivity, but this increase was mainly at the 
expense of the blood results. 
Previous studies in the literature have demonstrated 
disappointing results with other TMs, such as CEA and 
SCC, in BALF (19-22). Several authors have even found 
higher or similar CEA levels in BALF from smokers, 
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FIG. 2 Curves of post-test probability in the lung cancer 
group for CYFRA 21-1. The maximal gain for a positive 
result in the test is the maximal distance from the positive 
predictive value (PPV) curve to diagonal (22%); the maxi- 
mal negative diagnostic gain is the distance from the 
l-negative predictive value (NPV) curve to diagonal (5%). 
chronic bronchitis or benign lung diseases than in lung 
cancer (23327). They speculated that this increase might be 
due to the release of TMs by the airway cells as a conse- 
quence of inflammation and epithelial damage associated 
with several injuries on the airway, infection or merely a 
smoking habit. CYFRA 21-1 is present in the surface of 
tracheobronchial epithelial airway, but in the presence of 
cellular necrosis, a fragment of CYFRA can be released 
into the blood (2829). Curiously, significantly higher blood 
CYFRA 21-1 levels were found in patients with lung cancer 
than in the benign lung diseases group, but not in BALF. In 
fact, no correlation between the blood and BALF levels was 
detected, and the authors have no explanation for these 
results. However, it may be speculated that the presence 
of inflammation caused by benign diseases might promote 
the release of this cytokeratin into the airway, and even 
self instillation of saline solution could contribute to its 
liberation by the airway epithelium. 
Interestingly, in another biological fluid, pleural fluid, 
Romero et al. (30) found that CYFRA 21-1 showed a poor 
diagnostic value in neoplastic diseases. These authors pre- 
clude the use of CYFRA 21-1 in this fluid as a TM because 
it was also raised in several benign conditions as expression 
of a local inflammatory or repairing reaction. 
When applying a Bayesian analysis to the present results, 
as expected, information about diagnostic value was not 
improved. At difference pretest probabilities, the predictive 
values (positive and negative) reached by CYFRA 21-1 in 
BALF were poor. That is, after a test result, CYFRA 21-1 
levels in BALF are not useful either to confirm or to discard 
the existence of lung cancer. 
Another way to evaluate the usefulness of TMs in BALF 
in lung cancer is by comparing results between the lung 
bearing a tumour and the opposite lung. When this was 
done, CYFRA 21-1 only showed statistical significance 
when the results were not referred to total protein. Stockley 
et al. (19) in a similar study, found that CEA levels were 
raised in the cancer-involved lung with respect to the 
opposite lung in patients with cancer. On the other hand 
Wesselius et al. (4) reported no differences in CEA and 
BALF between neoplastic and non-neoplastic lungs, but the 
BALF from the cancer-involved lung was obtained first, 
hence fluid could enter into the opposite lung. 
In summary, a poor diagnostic value for CYFRA 21-1 in 
BALF was found, despite better results obtained in blood, 
with very low sensitivity when a high specificity is required. 
Also, no correlation with the tumour stage or histological 
cell types and CYFRA 21-1 levels was found. Bayesian 
analyses have demonstrated small predictive values at 
several prevalences. 
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